Related Experiment Video

Updated: May 30, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Anti-DLL4, a cancer therapeutic with multiple mechanisms of action

Austin Gurney1, Timothy Hoey

  • 1OncoMed Pharmaceuticals, 800 Chesapeake Drive, Redwood City, California 94063, USA. austin.gurney@oncomed.com.

Vascular Cell
|August 12, 2011
PubMed

Insights

Delta-like ligand 4 (DLL4) is crucial for normal development and cancer. Targeting DLL4 shows promise for anti-cancer therapies by inhibiting cancer stem cells and angiogenesis.

Area of Science:

  • Biochemistry
  • Developmental Biology
  • Oncology

Background:

  • Delta-like ligand 4 (DLL4) is a key Notch receptor ligand.
  • DLL4 plays vital roles in development, homeostasis, and stem cell biology.
  • Notch signaling is implicated in cancer stem cell (CSC) maintenance and proliferation.

Purpose of the Study:

  • To investigate the role of DLL4 in cancer stem cell (CSC) maintenance and proliferation.
  • To explore the potential of DLL4 as a target for anti-angiogenic therapy.
  • To evaluate the anti-tumor efficacy of targeting DLL4.

Main Methods:

  • Preclinical studies were conducted to assess DLL4's functions.
  • Investigated DLL4's role in cancer stem cell (CSC) biology.
  • Examined DLL4's contribution to angiogenesis.

Main Results:

  • DLL4 is important for cancer stem cell (CSC) maintenance and proliferation.
  • DLL4 plays a significant role in angiogenesis.
  • Preclinical data indicate that targeting DLL4 has anti-tumor effects.

Conclusions:

  • DLL4 targeting exhibits both anti-CSC and anti-angiogenic activities.
  • Anti-DLL4 antibodies demonstrate potential for cancer treatment.
  • Further clinical development of anti-DLL4 therapies is supported by preclinical findings.

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.